Has the quality of reporting improved for published case reports of adverse drug events?

被引：0
|
作者：
Williams, Evan A. [1 ]
Kane-Gill, Sandra L. [1 ]
机构：
[1] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
来源：
PHARMACOTHERAPY | 2014年 / 34卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
41
引用
收藏
页码：E85 / E86
页数：2
相关论文
共 50 条
  • [41] PomalidomideLung adverse events: 2 case reports
    Reactions Weekly, 2023, 1952 (1) : 297 - 297
  • [42] DoxorubicinHepatobiliary adverse events: 16 case reports
    Reactions Weekly, 2015, 1569 (1) : 101 - 101
  • [43] DolutegravirNeuropsychiatric adverse events: 3 case reports
    Reactions Weekly, 2017, 1671 (1) : 167 - 167
  • [44] AntineoplasticsOcular adverse events: 40 case reports
    Reactions Weekly, 2021, 1838 (1) : 60 - 60
  • [45] NilotinibCardiac adverse events: 7 case reports
    Reactions Weekly, 2013, 1443 (1) : 30 - 30
  • [46] Spontaneous reporting of adverse drug reactions: Who reports and what?
    Tubert-Bitter, P
    Haramburu, F
    Begaud, B
    Chaslerie, A
    Abraham, E
    Hagry, C
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 1998, 7 (05) : 323 - 329
  • [47] A SYSTEMATIC REVIEW AND META ANALYSIS OF THE EVIDENCE FROM THE PUBLISHED CASE REPORTS AND VACCINE ADVERSE EVENTS REPORTING SYSTEMS FOR THE MYOCARDITIS FOLLOWING COVID-19 VACCINATION
    Mehta, Ashwani
    Suman, Praveen
    Garg, Shreya
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 2065 - 2065
  • [48] Has the reporting quality of published randomised controlled trial protocols improved since the SPIRIT statement? A methodological study
    Tan, Zet Wei
    Tan, Aidan Christopher
    Li, Tom
    Harris, Ian
    Naylor, Justine M.
    Siebelt, Michiel
    van Tiel, Jasper
    Pinheiro, Marina
    Harris, Laura
    Chamberlain, Kira
    Adie, Sam
    BMJ OPEN, 2020, 10 (08):
  • [49] CASE-REPORTS OF UNTOWARD DRUG-REACTIONS, ADVERSE EVENTS, AND RARE DISEASES
    SOFFER, A
    ARCHIVES OF INTERNAL MEDICINE, 1982, 142 (07) : 1271 - 1272
  • [50] Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate
    Dorr, David A.
    Burdon, Rachel
    West, Dennis P.
    Lagman, Jennifer
    Georgopoulos, Christina
    Belknap, Steven M.
    Mckoy, June M.
    Djulbegovic, Benjamin
    Edwards, Beatrice J.
    Weitzman, Sigmund A.
    Boyle, Simone
    Tallman, Martin S.
    Talpaz, Moshe
    Sartor, Oliver
    Bennett, Charles L.
    CLINICAL CANCER RESEARCH, 2009, 15 (11) : 3850 - 3855
12345